Who
Antony C. Mattessich
Director
Company insider
Files Form 4 as: Director, Aura Biosciences; President and CEO, Ocular Therapeutix.
In numbers
- Trades disclosed
- 31
- Buys
- 6
- Sells
- 3
- Bought
- $501K
- Sold
- $270K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 20 Jun 2017
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,500 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 5 Feb 2024filed 6 Feb 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $95K19,642 at $4.86 | filing |
| 3 Feb 2024filed 6 Feb 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —549,400 at $0.00 | filing |
| 3 Feb 2024filed 6 Feb 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —180,400 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $91K18,338 at $4.95 | filing |
| 30 Aug 2023filed 5 Sep 2023 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Bought | $25K6,500 at $3.81 | filing |
| 7 Jun 2023filed 9 Jun 2023 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 6 Feb 2023filed 8 Feb 2023 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $83K19,669 at $4.24 | filing |
| 30 Jan 2023filed 1 Feb 2023 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —536,900 at $0.00 | filing |
| 30 Jan 2023filed 1 Feb 2023 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —176,300 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 3 Feb 2022filed 7 Feb 2022 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —560,200 at $0.00 | filing |
| 3 Feb 2022filed 7 Feb 2022 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —186,750 at $0.00 | filing |
News
Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 SharesOCUL · themarketsdaily.com · 15 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Upgraded to Strong-Buy at UBS GroupOCUL · dailypolitical.com · 14 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)OCUL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Antony C. Mattessich; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.